PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer

Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC)

(2018) Young Kwang Chae et al.   Scientific Reports

Advanced non-small cell lung cancer: the role of PD-L1 inhibitors

(2018) David F. Heigener et al.   Journal of Thoracic Disease

Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer

(2018) D.E. Meyers et al.   Current Oncology

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance

(2017) Susanne Horn et al.   JNCI-Journal of the National Cancer Institute

Disruption of the 3D cancer genome blueprint

(2017) Joanna Achinger-Kawecka et al.   Epigenomics

PD1 signal transduction pathways in T cells

(2017) Hugo Arasanz et al.   Oncotarget

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2017) Angel Garcia-Diaz et al.   Cell Reports

Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance

(2017) Susanne Horn et al.   JNCI-Journal of the National Cancer Institute

PD-L1 protein expression in non-small cell lung cancer based on different immunohistochemical antibodies

(2017) Minghui Zhang et al.   Journal of Thoracic Disease

PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis

(2017) Minghui Zhang et al.   Scientific Reports

The 3D Genome as Moderator of Chromosomal Communication

(2016) Job Dekker et al.   CELL

Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis

(2016) Omar Abdel-Rahman   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer

(2016) Jordi Remon et al.   CURRENT OPINION IN ONCOLOGY

Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors

(2016) Jonathan M. Pitt et al.   IMMUNITY

Genetic and Epigenetic Regulation of PD-1 Expression

(2016) Alexander P. R. Bally et al.   JOURNAL OF IMMUNOLOGY

PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non–Small Cell Lung Cancer

(2016) Seiichi Ikeda et al.   Journal of Thoracic Oncology

Regulation of disease-associated gene expression in the 3D genome

(2016) Peter Hugo Lodewijk Krijger et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

(2016) Daniel Sanghoon Shin et al.   Cancer Discovery

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis

(2016) Francesco Passiglia et al.   Oncotarget

The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis

(2015) A. Wang et al.   EJSO

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

(2015) Lieping Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Molecular Signatures Database Hallmark Gene Set Collection

(2015) Arthur Liberzon et al.   Cell Systems

Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer

(2015) Jiabei He et al.   Scientific Reports

The PD-1/PD-Ls pathway and autoimmune diseases

(2014) Suya Dai et al.   CELLULAR IMMUNOLOGY

RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance

(2014) Yanping Xiao et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression

(2014) Limo Chen et al.   Nature Communications

The Cancer Genome Atlas Pan-Cancer analysis project

(2013) John N Weinstein et al.   NATURE GENETICS

The Genotype-Tissue Expression (GTEx) project

(2013) John Lonsdale et al.   NATURE GENETICS

Programmed Death Ligand 2 in Cancer-Induced Immune Suppression

(2012) Esdy N. Rozali et al.   Clinical & Developmental Immunology

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Topological domains in mammalian genomes identified by analysis of chromatin interactions

(2012) Jesse R. Dixon et al.   NATURE

The role of the PD-1 pathway in autoimmunity and peripheral tolerance

(2011) Brian T. Fife et al.   Annals of the New York Academy of Sciences

Both Gene Amplification and Allelic Loss Occur at 14q13.3 in Lung Cancer

(2010) T. Harris et al.   CLINICAL CANCER RESEARCH

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

(2009) Loise M. Francisco et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Comprehensive Mapping of Long-Range Interactions Reveals Folding Principles of the Human Genome

(2009) E. Lieberman-Aiden et al.   SCIENCE